National and Kapodistrian University of Athens
Ανάπτυξη και επικύρωση υπερ-ευαίσθητων συνοδών διαγνωστικών εξετάσεων στα πλαίσια της υγρής βιοψίας (κυκλοφορούντα καρκινικά κύτταρα και ελεύθερο-κυττάρων DNA)
Abstract
dc:descriptionDuring the last years, liquid biopsy has overcome the limitations of tumor biopsy, changinh significantly the therapeutic strategy in cancer patients. Liquid biopsy is based on the analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Personalised medicine is based on the clinical evaluation of tumor biomarkers (DNA mutations, epigenetic alterations etc), which create a unique genetic profile of the patient and provides the right treatment to the patient on the right timeIn the present PhD thesis, we initially evaluated the presence of PIK3CA hotspot mutations in plasma-ctDNA samples from patients with early and metastatic breast cancer using a highly sensitive and analytically validated methodology based on the combination of of allele-specific, asymmetric rapid PCR and melting curve analysis. Moreover, a direct comparison study of PIK3CA hotspot mutations was performed in DNAs isolated from CellSearch® cartridges and paired plasma-ctDNA in identical blood draws using the same methodology in early and metastatic breast cancer patients. The results of our study were compared with the results based on ddPCR and a high concordance between our assay and ddPCR was demonstrated.Furthermore, we developed four novel assays for the detection of ESR1 mutations (Y537C, Y537N, Y537S, D538G), in liquid biopsy samples. This methodology is based on the combination of allele-specific, asymmetric rapid PCR and melting curve analysis. The clinical validation of this methodology was performed in DNAs isolated from CTCs of CellSearch® cartridges from metastatic ER(+) breast cancer patients. The results showed that ESR1 mutations were identified at high percentages in cases where detactable CTCs were identified by the CellSearch® system.We additionally performed a direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients. The overall agreement between these two methodologies was very high, indicating that both assays are suitable for the assessment of circulating BRAF-mutant ctDNA. High overall agreements were demonstrated when comparing the detection of BRAF V600E mutation in plasma using both methods with tissue testing. Half of the clinical samples which were BRAF V600E tumor positive were found to be positive in matched plasma-ctDNA samples for the same mutation. Interestingly, our study revealed a dependence of the correctness of plasma-based genotyping results on the sample storage duration highlighting the impact of pre-analytical factors.Finally, we developed and clinically validated a highly sensitive and specific RT-qPCR assay for the detection of PIM-1 mRNA expression in CTCs. Using this assay, we detected PIM-1 overexpression at a high frequency in EpCAM(+) fractions of metastatic castration resistant prostate cancer patients (mCRPC). Our data showed for the first time that detection of CTCs overexpressing PIM-1 is feasible, suggesting PIM-1 as a potential biomarker for prostate cancer management.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tzanikou, Eleni
- Τζανίκου, Ελένη
Subjects
dc:subject × 16Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46480